- Home
- CPBI vs IVVD Comparison
CPBI vs IVVD Comparison
Compare CPBI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | IVVD |
|---|---|---|
| Founded | 2023 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 692.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CPBI | IVVD |
|---|---|---|
| Price | $16.45 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 4.8K | ★ 12.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | $19,961,000.00 | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | 9.30 | ★ 332.71 |
| 52 Week Low | $13.00 | $0.35 |
| 52 Week High | $16.71 | $3.07 |
Technical Indicators
Market Signals| Indicator | CPBI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 54.13 |
| Support Level | $16.26 | $2.15 |
| Resistance Level | $16.55 | $2.59 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 85.29 | 50.50 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.